ZBTB20 and acute myeloid leukemia: In AML, miR-192 suppresses cancer progression by targeting CCNT2 [45], ULK1 [100], and ZBTB20 [101], with additional anti-tumor effects linked to modulation of the WNT signaling pathway [102].